Alex Wyatt
@ResearchWyatt
Followers
2K
Following
3K
Media
192
Statuses
1K
Prostate cancer genomics and ctDNA. Associate Prof for a precision oncology team @VanProstateCtr @UBCmedicine @BCCancer_GSC
Vancouver, British Columbia
Joined August 2017
Here’s our @Nature paper on v deep whole-genome sequencing of serial ctDNA and met tissue. @cherberts1, Matti, Joonatan et al applied new methods to give fascinating insight into temporal #ProstateCancer clonal complexity and evolution of resistance. 1/7
44
177
636
RT @urotoday: Understanding ctDNA technology applications for cancer detection and characterization. @ResearchWyatt @VanProstateCtr joins @….
0
5
0
RT @DrDrAprilRose: Really honoured to get to collaborate on this @CDNCancerTrials PC-BETS study. and to present substudy G at #ASCO25 - car….
0
4
0
RT @DrMHofman: Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur. ■ ¹⁷⁷Lu-PSMA-617: highe….
0
16
0
RT @urotoday: Substudy C of the Canadian Cancer Trials Group IND.234 PC_BETS—A phase II study of darolutamide selected by androgen-receptor….
0
8
0
RT @DrMHofman: Stunning research from @EdmondMKwan on ctDNA in theranostics:.🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. ca….
0
45
0
RT @EdmondMKwan: So many to thank that played an outsized role in making this possible. Special mention to close friends in @ResearchWyatt….
0
3
0
RT @EdmondMKwan: On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP s….
0
42
0
RT @DrMHofman: Hot of the press in @JournalofNucMed . with 10 years experience in Lutetium-177 PSMA radioligand therapy we describe a 1.3….
0
40
0
RT @DrChoueiri: Elegant presentation from @ResearchWyatt on the evolution of ctDNA detection and characterization! Session chaired by @Dana….
0
17
0
RT @DrYukselUrun: 🔥 ctDNA Testing: Smoke Detector vs. Fire Investigation! 🔥 Nice analogy by @ResearchWyatt .🧬🧬🧬Not all ctDNA tests serve th….
0
8
0
Thank you to funders, especially to @tfri_research for supporting this prostate cancer research in my team! We're applying cfChIP-seq to more patient samples in 2025 including a big expansion to advanced bladder cancer via generous grant support from @BladderCancerUS.
0
1
4
I'm not sure cfChIP-seq is *immediately* clinic-ready partly because low ctDNA% samples are much less informative, but I’m excited to see where M Freedman, @jberchuck, @SylvanBacaLab, and other pioneers will take this emerging technology in prostate cancer!.
1
0
4
At the moment, I think of this technique (plasma cfChIP-seq) as a tool to help us learn about metastatic biology, treatment resistance and therapeutic vulnerabilities - in 1000s of patients and in a way that wasn’t previously possible in a bone-predominant cancer.
1
0
2
What we can learn from histone modifications on prostate cancer ctDNA? Here’s our collaboration with David Takeda (NIH) where we performed cfChIP-seq for H3K4me2 on ctDNA from an aggressive set of mCRPC. Insights into patient-to-patient disease biology!
1
8
36
RT @VanAllenLab: Here's our latest, led by Drs. Riaz Gillani & @RyanLCollins13 - we studied a type of inherited genetic event (structural v….
science.org
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using...
0
47
0
RT @scottdehm: Our paper out today in @NatureComms analyzed plasma from the phase 3 @ALLIANCE_org A031201 trial using the AR-ctDETECT assay….
0
14
0
RT @AndreaMiyahira: The last time Felix stood on our stage, after a beautiful talk by @mishabeltran & intro by @AminaZoubeidi .💔💔💔 .https:….
0
12
0
RT @lack_lab: How does AR activation affect gene expression? Our new paper shows it’s less about creating new loops and more about amplifyi….
0
7
0